Clinical trial · Observational
Basal Cell Carcinoma Recurrence After Mohs Surgery
Basal Cell Carcinoma Recurrence
NCT00882791CI-TRIAL-00055348completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects. Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement. Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Historical Arm
- description
- 266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
- label
- Prospective Arm
- description
- 300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
Primary outcomes (1)
- measure
- Recurrence of BCC
- timeFrame
- either after 1 study visit (historical arm), or 3 years (prospective arm)
Secondary outcomes (1)
- measure
- Risk Factors for recurrence of BCC
- timeFrame
- either after 1 study visit (historical arm), or 3 years (prospective arm)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects with BCC lesions on the head, neck, genitalia, hands, or feet * Subjects who have undergone Mohs micrographic surgery for BCC on or before December 31, 2006 * Subjects with a medical record at the respective site * Subjects in a stable health condition, as determined by the principle investigator Exclusion Criteria: * Subjects with basal cell nevus syndrome * Subjects with lesions only in areas other than the head, neck, genitalia, * hands and feet * Subjects who have not followed up through the Department of Dermatology * Subjects with recurrent BCC lesions diagnosed on or prior to the recorded date of Mohs surgery
References
Publications (3)
- BACKGROUNDMehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of Basal cell carcinoma after mohs surgery in patients with chronic lymphocytic leukemia. Arch Dermatol. 2004 Aug;140(8):985-8. doi: 10.1001/archderm.140.8.985. PMID 15313816
- BACKGROUNDRobinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol. 2000 Nov;136(11):1318-24. doi: 10.1001/archderm.136.11.1318. PMID 11074691
- BACKGROUNDDubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol. 1983 May;119(5):373-7. PMID 6847215